Nutriband Inc. (NASDAQ: NTRB) announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to strengthen intellectual property protection for its AVERSA (TM) abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology's abuse-deterrent properties. If granted, the patent could extend protection for AVERSA (TM)-based products, including AVERSA (TM) FENTANYL, through 2046.
Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulants. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA (TM) abuse-deterrent technology. AVERSA (TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband.com.
The filing underscores Nutriband's commitment to protecting its innovative technology and could significantly extend the commercial exclusivity of its AVERSA-based products. If the patent is granted, it would provide Nutriband with a longer period to capitalize on its investment in research and development, potentially increasing the value of its intellectual property portfolio. This move is particularly important in the pharmaceutical industry, where patent protection is crucial for recouping the costs of developing new therapies and for attracting investment. For investors, the news signals proactive management of intellectual property, which can be a key driver of long-term growth and competitive advantage.
For those seeking more information, the full press release is available at https://ibn.fm/Osmxh. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
MissionIR (MissionIR), a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
This news is significant for the pharmaceutical and investment communities as it highlights ongoing efforts to combat opioid abuse through innovative drug delivery systems. The potential patent extension could provide Nutriband with a competitive edge in the growing market for abuse-deterrent medications, ultimately benefiting patients and shareholders alike.
